Andrea Sitlinger, MD, Duke University Cancer Institute

Articles by Andrea Sitlinger, MD, Duke University Cancer Institute

Advice for Community Oncologists on Treating HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Treatments for Relapsed/Refractory HCL in Pipeline

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

The Role of CD22-targeted Immunotoxins in HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Landscape Change in the Treatment of Relapsed/Refractory HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Historical Treatment for Relapsed/Refractory HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Combination First-line Therapy in Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Determining When to Treat and First-Line Therapy for HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Differential Diagnosis and Molecular Tests in Identifying HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Signs and Tests for Diagnosis and Prognosis of HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Molecular Genetic Changes for Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Introduction and Epidemiology of Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Latest Updated Articles

Differential Diagnosis and Molecular Tests in Identifying HCL
June 30th 2020
Advice for Community Oncologists on Treating HCL
June 30th 2020
$Landscape Change in the Treatment of Relapsed/Refractory HCL$
Landscape Change in the Treatment of Relapsed/Refractory HCL
June 30th 2020
Molecular Genetic Changes for Hairy Cell Leukemia
June 30th 2020
Signs and Tests for Diagnosis and Prognosis of HCL
June 30th 2020
When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL
June 30th 2020

Trending on OncLive

FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

VIR-5500 Receives FDA Fast Track Designation in mCRPC

September Roundup of FDA Approvals in Oncology: 8 Decisions to Know

Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC